Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$3.46 -9.4%	$2.85	$2.00 ▼ $5.00	$16.12M	2.2	7.18 million shs	164,851 shs
CVM CEL-SCI	$8.70 +6.9%	$4.76	$1.98 ▼ $39.30	$59.88M	0.52	373,871 shs	191,701 shs
DTIL Precision BioSciences	$4.71 -1.3%	$4.67	$3.61 ▼ $11.09	$55.52M	1.52	167,211 shs	106,424 shs
HOWL Werewolf Therapeutics	$1.33 +0.8%	$1.23	$0.60 ▼ $4.18	$59.68M	0.63	207,762 shs	239,697 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	0.00%	+8.81%	+23.57%	+27.25%	-4.62%
CVM CEL-SCI	0.00%	+16.94%	+108.63%	+30.04%	-74.78%
DTIL Precision BioSciences	0.00%	+7.53%	+1.51%	0.00%	-47.43%
HOWL Werewolf Therapeutics	0.00%	+13.68%	-5.00%	+19.82%	-33.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	0.5839 of 5 stars	0.0	3.0	0.0	2.3	1.7	0.0
CVM CEL-SCI	1.2199 of 5 stars	0.0	4.0	0.0	2.3	1.7	0.6
DTIL Precision BioSciences	4.1212 of 5 stars	3.5	1.0	4.6	3.4	1.7	0.6
HOWL Werewolf Therapeutics	3.5866 of 5 stars	3.5	5.0	0.0	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
CVM CEL-SCI	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	897.88% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	526.57% Upside

Current Analyst Ratings Breakdown

Latest AIMD, HOWL, CVM, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	806.18	N/A	N/A	$2.46 per share	1.41
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
DTIL Precision BioSciences	$1.26M	44.03	N/A	N/A	$2.89 per share	1.63
HOWL Werewolf Therapeutics	$1.14M	52.22	N/A	N/A	$1.65 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$4.99	N/A	∞	N/A	N/A	-108.25%	-56.94%	8/18/2025 (Estimated)
CVM CEL-SCI	-$26.92M	-$9.77	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
HOWL Werewolf Therapeutics	-$70.51M	-$1.64	N/A	N/A	N/A	N/A	-99.71%	-58.64%	N/A

Latest AIMD, HOWL, CVM, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	-$0.40	+$0.10	-$0.40	$1.50 million	N/A
8/13/2025	Q2 2025	AIMD Ainos	N/A	-$0.99	N/A	-$0.99	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.96	2.88	1.91
CVM CEL-SCI	0.66	1.07	1.09
DTIL Precision BioSciences	0.66	5.18	5.18
HOWL Werewolf Therapeutics	0.46	8.09	8.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
CVM CEL-SCI	12.08%
DTIL Precision BioSciences	37.99%
HOWL Werewolf Therapeutics	64.84%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
CVM CEL-SCI	9.93%
DTIL Precision BioSciences	4.50%
HOWL Werewolf Therapeutics	23.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	4.66 million	4.17 million	Not Optionable
CVM CEL-SCI	43	6.88 million	64.67 million	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable

AIMD, HOWL, CVM, and DTIL Headlines

Recent News About These Companies

Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions

August 16 at 2:13 AM | msn.com

Werewolf Therapeutics Reports Q2 2025 Financial Results

August 14 at 12:15 AM | tipranks.com

Werewolf Therapeutics sees cash runway into 4Q26

August 14 at 11:55 AM | msn.com

Werewolf Therapeutics Reports Q2 2025 Financial Results

August 14 at 11:55 AM | msn.com

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

Werewolf Therapeutics (HOWL) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Werewolf Therapeutics (NASDAQ:HOWL) Trading Up 0.8% - Time to Buy?

August 1, 2025 | marketbeat.com

ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer

July 29, 2025 | finance.yahoo.com

Howling Hits: The Ultimate List of Must-Watch Werewolf Movies

July 17, 2025 | msn.com

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

July 9, 2025 | globenewswire.com

Werewolf Therapeutics, Inc. (HOWL) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Werewolf Therapeutics to Participate in the BIO International Convention

June 12, 2025 | globenewswire.com

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

May 29, 2025 | zacks.com

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential

May 24, 2025 | investing.com

Werewolf Therapeutics Stock Price, Quotes and Forecasts

May 20, 2025 | benzinga.com

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 20, 2025 | globenewswire.com

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Acquires $159,288.22 in Stock

May 15, 2025 | insidertrades.com

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 13, 2025 | globenewswire.com

Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | finanznachrichten.de

Werewolf Therapeutics Announces Q1 2025 Financial Results

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD, HOWL, CVM, and DTIL Company Descriptions

Ainos NASDAQ:AIMD

$3.46 -0.36 (-9.42%)

As of 08/15/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

CEL-SCI NYSE:CVM

$8.70 +0.56 (+6.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.76 +0.06 (+0.74%)

As of 08/15/2025 07:59 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Precision BioSciences NASDAQ:DTIL

$4.71 -0.06 (-1.26%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.69 -0.02 (-0.42%)

As of 08/15/2025 07:51 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Werewolf Therapeutics NASDAQ:HOWL

$1.33 +0.01 (+0.76%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.32 -0.01 (-0.38%)

As of 08/15/2025 05:47 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time